Patents Examined by Jerry D. Johnson
-
Patent number: RE49530Abstract: A glass and an enclosure, including windows, cover plates, and substrates for mobile electronic devices comprising the glass. The glass has a crack initiation threshold that is sufficient to withstand direct impact, has a retained strength following abrasion that is greater than soda lime and alkali aluminosilicate glasses, and is resistant to damage when scratched. The enclosure includes cover plates, windows, screens, and casings for mobile electronic devices and information terminal devices.Type: GrantFiled: January 17, 2020Date of Patent: May 16, 2023Assignee: CORNING INCORPORATEDInventors: Kristen L. Barefoot, Matthew John Dejneka, Sinue Gomez, Timothy Michael Gross, Nagaraja Shashidhar
-
Patent number: RE49579Abstract: [Problem] Provided is a non-peptide compound which can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor including as an active ingredient a compound represented by the chemical formula 1 wherein R1, R2, and R3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, a polysulfurized derivative thereof, or a pharmaceutically acceptable salt thereof. The present compound has a GAPDH aggregation inhibitory activity to suppress intracerebral aggregation of various proteins involved in cerebral neurodegenerative diseases, thereby contributing to improvement in various brain neurological diseases associated with aggregation of these proteins such as Alzheimer's disease, Parkinson's disease, and cerebral infarction, and prevention of advanced seriousness of these diseases.Type: GrantFiled: November 24, 2020Date of Patent: July 18, 2023Assignee: UNIVERSITY PUBLIC CORPORATION OSAKAInventor: Hidemitsu Nakajima
-
Patent number: RE49699Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Patent number: RE49735Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: September 22, 2021Date of Patent: November 28, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael Frederick Parker
-
Patent number: RE49741Abstract: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.Type: GrantFiled: June 12, 2020Date of Patent: December 5, 2023Assignee: Vivesto ABInventors: Julian Aleksov, Igor Lokot
-
Patent number: RE49742Abstract: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.Type: GrantFiled: February 17, 2021Date of Patent: December 5, 2023Assignee: Vivesto ABInventors: Julian Aleksov, Igor Lokot
-
Patent number: RE49758Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.Type: GrantFiled: January 21, 2021Date of Patent: December 19, 2023Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
-
Patent number: RE49811Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.Type: GrantFiled: March 7, 2022Date of Patent: January 23, 2024Assignee: Apogee Biotechnology CorporationInventors: Charles D. Smith, Kevin J. French, Yan Zhuang
-
Patent number: RE49850Abstract: A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.Type: GrantFiled: February 2, 2022Date of Patent: February 27, 2024Assignee: AUCENTRA THERAPEUTICS PTY LTDInventors: Shudong Wang, Solomon Tadesse Zeleke, Mingfeng Yu
-
Patent number: RE49880Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: March 26, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Alaric J. Dyckman, Dharmpal S. Dodd, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Ramesh Kumar Sistla
-
Patent number: RE49893Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: April 2, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Hague, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
-
Patent number: RE49909Abstract: The present invention refers to a process for reducing the amount of undesired components in an oil composition, particularly in an oil composition comprising omega-3 polyunsaturated fatty acids. The process of the present invention provides efficient removal of undesired water-soluble (hydrophilic) components and undesired fat-soluble (lipophilic) components from an oil composition in order to obtain a purified concentrate, e.g. a highly purified concentrate enriched in omega-3 polyunsaturated fatty acids.Type: GrantFiled: March 14, 2019Date of Patent: April 9, 2024Assignee: BASF ASInventors: Sverre Sondbø, Olav Thorstad
-
Patent number: RE49931Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: April 23, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar
-
Patent number: RE49934Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.Type: GrantFiled: March 8, 2022Date of Patent: April 23, 2024Assignee: Servier Pharmaceuticals LLCInventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
-
Patent number: RE50029Abstract: A method of forming a nanostructure comprises forming a directed self-assembly of nucleic acid structures on a patterned substrate. The patterned substrate comprises multiple regions. Each of the regions on the patterned substrate is specifically tailored for adsorption of specific nucleic acid structure in the directed self-assembly.Type: GrantFiled: April 14, 2021Date of Patent: July 2, 2024Assignee: Micron Technology, Inc.Inventors: Scott E. Sills, Gurtej S. Sandhu
-
Patent number: RE50040Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: March 2, 2022Date of Patent: July 16, 2024Assignee: VYLUMA INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Patent number: RE50049Abstract: Novel isohexides and pharmaceutical compositions containing the same as well as methods of using the same in the treatment of psoriasis.Type: GrantFiled: June 28, 2021Date of Patent: July 23, 2024Assignee: Sytheon Ltd.Inventors: Ratan K Chaudhuri, Krys Bojanowski
-
Patent number: RE50050Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: March 19, 2022Date of Patent: July 23, 2024Assignee: MyoKardia, Inc.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
-
Patent number: RE50062Abstract: A process for producing acetic acid by: a reaction step for continuously allowing methanol to react with carbon monoxide in the presence of a catalyst system comprising a metal catalyst, an ionic iodide, and methyl iodide in a carbonylation reactor, a flash distillation step for continuously feeding a flasher with a reaction mixture from the reactor and evaporating a volatile component at least containing product acetic acid, methyl acetate, and methyl iodide by flash distillation to separate the volatile component and a liquid catalyst mixture at least containing the metal catalyst and the ionic iodide, and an acetic acid collection step for separating a stream containing acetic acid from the volatile component to collect acetic acid; wherein, in the flash distillation step, the flash distillation is conducted under the condition that the concentration of methyl acetate in the liquid catalyst mixture is not less than 0.6% by weight.Type: GrantFiled: December 12, 2019Date of Patent: July 30, 2024Assignee: DAICEL CORPORATIONInventors: Masahiko Shimizu, Ryuji Saito, Hiroyuki Miura, Takashi Ueno, Hidehiko Nakajima
-
Patent number: RE50083Abstract: Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on hURAT1-transported uric acid in HEK293 transfected cells, and show that such compounds have a good potential for application in the treatment of hyperuricemia or gout.Type: GrantFiled: March 29, 2022Date of Patent: August 20, 2024Assignee: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Jianghua Zhu, Jie Gu